Why the study?
Diagnosing cardiac sarcoidosis is challenging due to variable presentation and lack of consensus on screening, prompting evaluation of FDG-PET/CT in patients with normal CMR and no high-risk cardiac features.
Does FDG-PET/CT provide diagnostic and prognostic value in patients with extracardiac sarcoidosis, no high-risk cardiac features, and normal CMR?
Does FDG-PET/CT provide diagnostic and prognostic value in patients with extracardiac sarcoidosis, no high-risk cardiac features, and normal CMR?
FDG-PET/CT offers limited diagnostic and prognostic value in patients with extracardiac sarcoidosis who have no high-risk cardiac features and normal CMR, a population that inherently has a low risk of adverse cardiac events.
Answers are grounded in this paper and cite their sources.
FDG-PET/CT adds limited value in low-risk sarcoidosis with normal CMR; leaves open its role in broader screening pending prospective data.
AIMS: Diagnosing cardiac sarcoidosis (CS) is challenging due to the variable presentation and the lack of consensus on optimal screening strategies. Early identification is critical to prevent adverse outcomes. This study evaluates the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) in assessing CS in patients with no high-risk cardiac features and normal cardiac magnetic resonance (CMR). METHODS AND RESULTS: This retrospective, single-centre cohort included biopsy-confirmed extracardiac sarcoidosis patients who underwent CMR and FDG-PET/CT. Patients with no high-risk cardiac features and normal CMR were included. The primary outcome was the diagnostic value of FDG-PET/CT in the assessment for CS by a multi-disciplinary team (MDT). Secondary outcome included the occurrence of adverse cardiac events. In total, 305 (94.1%) patients were classified as 'unlikely CS', 17 (5.3%) as 'possible CS' and 2 (0.6%) as 'probable CS'. Cardiac FDG uptake was observed in 69 of 324 patients (21.3%). Within the MDT, FDG-PET/CT findings demonstrated limited diagnostic value, as 55.2% with uptake patterns suggestive of CS were ultimately classified as 'unlikely CS' based on other clinical and imaging findings. During a median follow-up of 38.1 months, the overall event rate was low: 15 events (3.4%; annualized 1.1%), with all five cardiac deaths occurring in the 'unlikely CS' group. Only five of 69 patients (7.2%) with cardiac FDG uptake experienced an adverse cardiac event. CONCLUSION: FDG-PET/CT offers limited diagnostic and prognostic value in sarcoidosis patients with no high-risk cardiac features and normal CMR. Our findings confirm that this population has a low risk of adverse cardiac events.
No takes yet. Share an insight, caveat, or question.
Shuduyeva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: